Program
daratumumab
Also written as “Daratumumab”, “Daratumumab SC” and “Daratumumab IV”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Myelodysplastic Syndromes · Lymphoma, Mantle-Cell, led by 4 companies.
Drug pageDaratumumab: every studyAll 219 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 284 open or running | phase 4since Nov 29, 2018 | Dec 14, 2007 | Jan 31, 2029phase 3 · NCT05438043 |
| Bristol-Myers Squibbits history only | 31 open or running | phase 3since Aug 16, 2018 | May 12, 2016 | none ahead |
| Amgen | 10 open or running | phase 3since May 9, 2017 | May 9, 2017 | none ahead |
| Celltrionits history only | 11 open or running | phase 3since Apr 29, 2025 | Apr 29, 2025 | Mar 8, 2027phase 3 · NCT06952478 |
Also a collaborator on its studies: Karyopharm Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2017First study: phase 3 study in Multiple MyelomaFirst studyNCT03158688 · 466 enrolled · United States, Australia, Austria and more
TargetBeta
“A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
The one study Amgen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03158688Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Jul 14, 2019 | 466 |
How it is read
Names in the registry
- “Daratumumab”, 32 entries
- “daratumumab”, 3 entries
- “Daratumumab SC”, 3 entries
- “Daratumumab IV”, 2 entries
- “CT-P44(Daratumumab)”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 37 studies
- Amyloidosis, 2 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Myelodysplastic Syndromes, 1 study
- Lymphoma, Mantle-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.